4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 65 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $610,725 | -32.7% | 29,096 | +2.1% | 0.00% | 0.0% |
| Q1 2024 | $907,691 | +77.1% | 28,490 | +12.6% | 0.00% | 0.0% |
| Q4 2023 | $512,436 | +48.2% | 25,293 | -6.9% | 0.00% | 0.0% |
| Q3 2023 | $345,734 | -46.2% | 27,159 | -23.7% | 0.00% | 0.0% |
| Q2 2023 | $643,220 | +39.6% | 35,596 | +32.8% | 0.00% | 0.0% |
| Q1 2023 | $460,830 | +73.2% | 26,808 | +123.8% | 0.00% | – |
| Q4 2022 | $266,076 | -6.6% | 11,980 | -66.2% | 0.00% | – |
| Q3 2022 | $285,000 | +13.1% | 35,469 | -1.7% | 0.00% | – |
| Q2 2022 | $252,000 | -49.1% | 36,083 | +10.2% | 0.00% | -100.0% |
| Q1 2022 | $495,000 | -36.6% | 32,746 | -8.1% | 0.00% | 0.0% |
| Q4 2021 | $781,000 | +30.2% | 35,614 | +60.0% | 0.00% | 0.0% |
| Q3 2021 | $600,000 | +84.0% | 22,265 | +64.2% | 0.00% | – |
| Q2 2021 | $326,000 | -36.0% | 13,558 | +15.5% | 0.00% | -100.0% |
| Q1 2021 | $509,000 | – | 11,737 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |